WJWei Jiang

Wei Jiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wei Jiang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Clifford V. Harding

    † Center for AIDS Research, Case Western Reserve University, University Hospitals/Case Medical Center, Cleveland, OH 44106

    2 shared publications
  • Michael M. Lederman

    Division of Infectious Diseases and HIV Medicine, Case Western Reserve University, University Hospitals/Case Medical Center, Cleveland, OH 44106

    2 shared publications
  • Scott F. Sieg

    Division of Infectious Diseases and HIV Medicine, Case Western Reserve University, University Hospitals/Case Medical Center, Cleveland, OH 44106

    2 shared publications
  • Benigno Rodriguez

    The American British Cowdray Medical Center, Mexico City, Mexico

    1 shared publication
  • Richard J. Mohner

    Division of Infectious Diseases, Center For AIDS Research, Department of Medicine, Case Western Reserve University and University Hospital of Cleveland, Cleveland, Ohio 44106,1 Department of Pathology, Center For AIDS Research, Case Western Reserve University, Cleveland, Ohio 441062

    1 shared publication
  • Todd M. Nedrich

    Division of Infectious Diseases, Center For AIDS Research, Department of Medicine, Case Western Reserve University and University Hospital of Cleveland, Cleveland, Ohio 44106,1 Department of Pathology, Center For AIDS Research, Case Western Reserve University, Cleveland, Ohio 441062

    1 shared publication

Latest Publications

  • Open Access

    Presentation of Soluble Antigens to CD8+ T Cells by CpG Oligodeoxynucleotide-Primed Human Naive B Cells

    by Wei Jiang, Michael M. Lederman, Clifford V. Harding, Scott F. Sieg

    Naive B lymphocytes are generally thought to be poor APCs, and there is limited knowledge of their role in activation of CD8+ T cells. In this article, we demonstrate that class I MHC Ag presentation by human naive B cells is enhanced by TLR9 agonists. Purified naive B cells were cultured with or without a TLR9 agonist (CpG oligodeoxynucleotide [ODN] 2006) for 2 d and then assessed for phenotype, endocytic activity, and their ability to induce CD8+ T cell responses to soluble Ags. CpG ODN enhanced expression of class I MHC and the costimulatory molecule CD86 and increased endocytic activity as determined by uptake of dextran beads. Pretreatment of naive B cells with CpG ODN also enabled presentation of tetanus toxoid to CD8+ T cells, resulting in CD8+ T cell cytokine production and granzyme B secretion and proliferation. Likewise, CpG-activated naive B cells showed enhanced ability to cross-present CMV Ag to autologous CD8+ T cells, resulting in proliferation of CMV-specific CD8+ T cells. Although resting naive B cells are poor APCs, they can be activated by TLR9 agonists to serve as potent APCs for class I MHC-restricted T cell responses. This novel activity of naive B cells could be exploited for vaccine design.


  • Impaired Naive and Memory B-Cell Responsiveness to TLR9 Stimulation in Human Immunodeficiency Virus Infection

    by Wei Jiang, Michael M. Lederman, Richard J. Mohner, Benigno Rodriguez, Todd M. Nedrich, Clifford V. Harding, Scott F. Sieg

    Toll-like receptor 9 (TLR9) agonists such as unmethylated bacterial CpG DNAs activate B lymphocytes directly, potentially influencing their function and homeostasis. To assess B-cell responsiveness to TLR9 agonists in human immunodeficiency virus (HIV) disease, we examined the ability of naive and memory B cells to proliferation and to increase surface expression of CD80 in response to CpG oligonucleotides (ODN). CpG ODN induced expression of CD80 similarly in B cells from HIV-infected persons and from healthy controls. In contrast, proliferation responses to CpG ODN were markedly impaired in both naive and memory B-cell subsets from HIV-infected persons. Naive B-cell proliferation defects were related to plasma HIV RNA and, among memory B cells, to the frequencies of CD21-negative cells. Importantly, TLR9 mRNA levels were significantly diminished in freshly prepared naive B cells and especially so in memory B cells from HIV-positive viremic donors, suggesting a possible underlying mechanism for the observed functional impairments. Dose-response studies indicated that optimal induction of CD80 expression was achieved with much lower concentrations of CpG ODN than optimal induction of proliferation. We propose that the relatively low threshold of activation that is required for CD80 induction by CpG ODN might explain the preservation of this response in B cells from HIV-infected persons despite diminished TLR9 expression. Impaired responsiveness to TLR9 agonists may contribute to defects in humoral immunity in HIV infection.